Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on November 5, 2018. The report details the termination of a material definitive agreement with Cantor Fitzgerald & Co.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. However, management states that estimated cash flow from operations is sufficient to fund operating expenses, capital expenditures, and working capital requirements for at least the next twelve months.
Material Changes
- Termination of Sales Agreement: The Company terminated the Controlled Equity Offering SM Sales Agreement dated November 27, 2015, with Cantor Fitzgerald & Co.
- Effective Date: The termination becomes effective on November 15, 2018, following a ten-day notice period.
- Reason for Change: The Company no longer requires the facility to sell common stock to fund its planned level of operations.
Outlook and Management Commentary
Management commentary indicates a shift in capital strategy. The Company estimates that internal cash generation will cover all operational and capital needs for the upcoming year, eliminating the immediate need for equity financing through the terminated sales agreement. No specific risks, contingencies, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the effective date of the termination (November 15, 2018) to ensure no further stock sales occur under the old agreement.
- Review subsequent quarterly reports (10-Q) to confirm the accuracy of the management's cash flow projections for the next twelve months.
- Check for any new financing agreements or capital raises filed after this date.